SOLESENCE, INC. — Director's Dealing 2024

Sep 3, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NANOPHASE TECHNOLOGIES Corp (NANX)
CIK: 0000883107
Period of Report: 2024-08-27

Reporting Person: WHITMORE R JANET (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-08-27	Common Stock	P	1177	$1.52	Acquired	1937958	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Deferred Common Stock	$		Common Stock (20030)	20030	Direct
Common Stock (right to purchase)	$0.9	2026-11-17	Common Stock (2000)	2000	Direct
Common Stock (right to purchase)	$1.05	2026-11-17	Common Stock (2000)	2000	Direct
Common Stock (right to purchase)	$1.18	2026-11-17	Common Stock (2000)	2000	Direct
Common Stock (right to purchase)	$0.84	2026-11-17	Common Stock (2000)	2000	Direct
Common Stock (right to purchase)	$1.85	2026-11-17	Common Stock (2000)	2000	Direct
Common Stock (right to purchase)	$1.10	2026-11-17	Common Stock (2000)	2000	Direct
Common Stock (right to purchase)	$0.99	2026-11-17	Common Stock (2000)	2000	Direct
Common Stock (right to purchase)	$0.68	2027-02-21	Common Stock (10000)	10000	Direct
Common Stock (right to purchase)	$0.82	2028-05-23	Common Stock (10000)	10000	Direct
Common Stock (right to purchase)	$0.45	2027-06-18	Common Stock (6667)	6667	Direct
Common Stock (right to purchase)	$4.17	2028-12-28	Common Stock (20000)	20000	Direct
Common Stock (right to purchase)	$1.165	2029-12-20	Common Stock (20000)	20000	Direct
Common Stock (right to purchase)	$0.61	2030-12-27	Common Stock (12600)	12600	Direct

Footnotes

F1: Each share of deferred common stock represents the right to receive one share of common stock.

F2: The deferred common stock becomes payable upon the reporting person's termination of service as a director of the Company.

F3: Pursuant to such plan, the reporting person elected to defer receipt of such shares and receive a cumulative total of 20,030 shares of deferred common stock which will all be accounted for under the Company's Non-Employee Director Deferred Compensaion Plan.

F4: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. Two-thousand shares were issued with an exercise price of $0.90, 2,000 were issued with an exercise price of $1.05, 2,000 were issued with an exercise price of $1.18, 2,000 were issued with an exercise price of $0.84, 2,000 were issued with an exercise price of $1.85. 2,000 were issued with an exercise price of $1.10, and 2,000 were issued with an exercise price of $0.99.

F5: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.